Mizuho Reiterates Buy Rating for ASMB, Sets $45 Price Target
Mizuho reiterates its Buy rating on ASMB, aiming for a $45 target, a 95.99% upside from the current price.
Key Points
- Mizuho reiterated its Buy rating on ASMB with a $45 price target on June 15, 2026.
- Mizuho's $45 price target implies 95.99% upside from Assembly Biosciences, Inc.'s ($ASMB) current $22.96 share price.
- ASMB shares are trading at $22.96, with recent insider buying activity noted.
- Peer funds like Janus Henderson increased their ASMB holdings, while other funds maintained their positions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, Mizuho reiterated its Buy rating on ASMB, setting a price target of $45. Analyst Salim Syed emphasized confidence in the stock's potential, with ASMB currently trading at $22.96.
Other Institutional Activity in ASMB
Janus Henderson Group PLC increased its holdings in ASMB by 11,384 shares, ending with 849,309 shares valued at approximately $23.48 million. Meanwhile, other major funds like Gilead Sciences, Inc., Farallon Capital Management LLC, and RA Capital Management, L.P., held steady with their positions, maintaining their share counts at 4,505,391, 1,227,590, and 1,020,410 shares respectively.
Assembly Biosciences, Inc. Stock Down 32.6%
ASMB shares are currently trading at $22.96. The stock has seen various analyst activities, with a notable Buy rating and a target price of $45 from Mizuho. This reflects confidence from analysts and investors despite the current trading price.
Insider Buying and Selling at Assembly Biosciences, Inc.
Several insiders, including John McHutchison, Susan Mahony, and Anthony Altig, each purchased 8,000 shares of ASMB on June 4, 2026. These transactions were not part of a pre-planned trading program, indicating personal confidence in the company's prospects.
Analysts Set New Price Targets
On June 15, 2026, Mizuho maintained its Buy rating on ASMB with a $45 price target. Earlier, on April 6, 2026, Guggenheim also maintained a Buy rating with a $43 target. Furthermore, HC Wainwright & Co. reiterated a Buy rating on March 26, 2026, with a higher target of $50. The consensus among analysts is a strong Buy recommendation.
About ASMB
ASMB operates in the biotechnology sector, focusing on developing innovative therapies for various diseases. The company is headquartered in the United States and works on advancing treatments that address unmet medical needs.
Bottom Line
Mizuho's reaffirmed Buy rating and $45 price target for ASMB highlight the firm's positive outlook on the stock. With ASMB trading at $22.96 and insider buying activity, there is interest in the company's future potential. It's important to remember that these analyst ratings and price targets are based on current data and can change over time.
Get Assembly Biosciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ASMB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.